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This review addresses the scope of phenotypic diversity
within Barrett’s esophagus. Although often under-
emphasized, the authors argue that this diversity may be key
to understanding Barrett’s initiation and progression.
Barrett’s esophagus is characterized by the erosive
replacement of esophageal squamous epithelium by a
range of metaplastic glandular phenotypes. These glan-
dular phenotypes likely change over time, and their dis-
tribution varies along the Barrett’s segment. Although
much recent work has addressed Barrett’s esophagus from
the genomic viewpoint—its genotype space—the fact that
the phenotype of Barrett’s esophagus is nonstatic points to
conversion between phenotypes and suggests that Barrett’s
esophagus also exists in phenotype space. Here we explore
this latter concept, investigating the scope of glandular
phenotypes in Barrett’s esophagus and how they exist in
physical and temporal space as well as their evolution and
their life history. We conclude that individual Barrett’s
glands are clonal units; because of this important fact, we
propose that it is the Barrett’s gland that is the unit of se-
lection in phenotypic and indeed neoplastic progression.
Transition between metaplastic phenotypes may be gov-
erned by neutral drift akin to niche turnover in normal and
dysplastic niches. In consequence, the phenotype of Bar-
rett’s glands assumes considerable importance, and we
make a strong plea for the integration of the Barrett’s gland
in both genotype and phenotype space in future work. (Cell
Mol Gastroenterol Hepatol 2015;1:41–54; http://dx.doi.org/
10.1016/j.jcmgh.2014.10.001)
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is replaced with glands composed of columnar
cells—columnar-lined esophagus. How and why does this
occur? Classically, this is explained by severe acid and bile
reﬂux destroying the stratiﬁed squamous epithelium, which
is replaced with columnar epithelial glands. Teleologically,
these are more resistant to acid/peptic digestion1 and have
a selective advantage over the squamous epithelium in the
harsh, mutagenic environment associated with reﬂux.2Recent progress has seen a step-change in our knowl-
edge of the changes in the genotype of Barrett’s gland with
time. Where initially we thought that Barrett’s segments
progressed to malignancy through a number of clonal se-
lective sweeps in well-deﬁned genes,3 it has recently
become clear that such selective sweeps, where mutations
spread clonally throughout the segment and become “ﬁxed,”
are rare indeed. Many patients with Barrett’s esophagus
maintain an equilibrium level of genetic alter-
ations—stasis—over time, but sometimes with infrequent
but signiﬁcant genetic change or punctuation caused by
growth of clones with huge numbers of genetic alter-
ations.2,4 The clonal dynamics in nonprogressor Barrett’s
genomes are thus stable over long periods, but patients who
progress develop substantially increased genetic changes in
a relatively short time frame: unexpectedly, this occurs
within just a few years before the development of cancer.2
Surprisingly, no attempt has been made to map these
genotypes to the changing phenotypes seen in Barrett’s
mucosa—sometimes referred to as a genotype–phenotype
map. Which phenotype(s) is prone to develop such cata-
strophic changes? Does such a correlation exist? Widening
the argument, why do the several phenotypes seen in Bar-
rett’s esophagus occur? Why and when may some pheno-
types be favored over others? What is the phylogenetic
relationship between these several phenotypes, and what, if
anything, does this say about the origin and development of
Barrett’s esophagus? Such questions have direct clinical
relevance: recent years have seen a sharpdisagreement about
which phenotype predisposes to cancer development,5,6
about who should be entered into surveillance and treat-
ment programs for Barrett’s esophagus,7,8 and indeed about
what the very deﬁnition is of Barrett’s esophagus itself.9–12
We investigate the range of glandular phenotypes
observed in Barrett’s esophagus and explore their relations
in phenotype space, which is formally deﬁned as an abstract
space containing every possible phenotype in a given bio-
logic system.13 When we try to think about Barrett’s
esophagus and especially Barrett’s glands in evolutionary
terms, it is not usual to consider it as a system where the
Figure 1. Barrett’s glands show functional compartmentalization. (A) H&E photomicrograph of a series of nondysplastic
Barrett’s glands (of canonical, specialized type) demonstrating abundant goblet cells. Note the mucous glands arranged as
small acini at the base of these Barrett’s gland (arrows). (B) Illustration of the Barrett’s glands shown in A. The stem cell zone
(shown in magenta) demonstrates maximal Ki-67 proliferative activity and LGR5 labeling on in situ hybridization. This prolif-
erative compartment is located about one-third up the glandular axis. Labeling studies demonstrate bidirectional ﬂow from this
stem cell compartment. Speciﬁcally, specialized epithelium (a combination of MUC5ACþ/TFF1þ foveolar cells and MUC2þ/
TFF3þ goblet cells, both shown in pink) migrates toward the luminal surface, while MUC6þ/TFF2þ mucous cells (shown in
blue) migrate toward the glandular base at a much slower rate. This functional compartmentalization replicates pyloric-type
gland organization.
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usually think of evolution in terms of selection—here, of
glands of different phenotypes being selected because of
their ﬁtness (or otherwise). Fitness would be deﬁned as the
ability of any Barrett’s gland phenotype to both survive and
reproduce. Conceptually, for any given ecologic niche, this
selection results in an optimal phenotype, which will occupy
a point in abstract phenotype space. However, where Bar-
rett’s glands are concerned, we do not know the nature of
the ﬁtness characteristic under selection: it could be, for
example, its ability to survive acid/peptic digestion,1 medi-
ated through its mucin/trefoil family peptide pattern of
expression, stress response phenotype,14 defense capac-
ity,15,16 or indeed simply its ability to (rapidly) reproduce
itself and clonally expand, which indeed has been
observed14 and thus is possibly related to a proliferative
phenotype.1 Conceivably, intergland competition could play
a role: perhaps some glands actively suppress the growth oftheir neighbors, leading to competitive phenotypes being
selected. Thus, a number of characteristics may collectively
contribute to ﬁtness. In this review, we put forth a number
of questions. What explains the protean manifestation of
Barrett’s esophagus? Why are such diverse gland pheno-
types selected? Alternatively, does an optimal phenotype
exist within Barrett’s esophagus? And ﬁnally, where in
phenotype space are the various metaplasias observed in
Barrett’s esophagus situated?
Gland Phenotypes in Barrett’s
Esophagus
Before we plot possible evolutionary trajectories in
Barrett’s phenotype space, we will need to deﬁne the phe-
notypes observed in Barrett’s esophagus. The canonical
Barrett’s gland displays so-called specialized metaplasia or
specialized epithelium (Figure 1A). Until recently, the unique
Table 1.Spectrum of Gland Phenotypes in Barrett’s Esophagus
Gland Phenotype Lineage Differentiation Marker References
Fundic-type gland Foveolar cell MUC5AC Vieth and Montgomery 201498
Parietal cell Hþ/Kþ-ATPase Choi et al 201433
Chief cell MIST1 Lennerz et al 201099
Oxyntocardiac gland Foveolar cell MUC5AC Vieth and Montgomery 201498
Parietal cell Hþ/Kþ-ATPase Choi et al 201433
Pyloric gland base MUC6 Choi et al 201433
Non-goblet columnar gland Foveolar cell MUC5AC Lavery et al 201417
Pyloric gland base MUC6 Lavery et al 201417
Barrett’s gland Foveolar cell MUC5AC Lavery et al 201417
Goblet cell MUC2 Lavery et al 201417
Barrett’s gland base MUC6 Lavery et al 201417
Barrett’s gland with Paneth cells Foveolar cell MUC5AC Lavery et al 201417
Goblet cell MUC2 Lavery et al 201417
Paneth cell CD24 Lennerz et al 201099
January 2015 Barrett’s Gland in Phenotype Space 43functional properties of this gland phenotype may not have
been properly appreciated. Specialized epithelium displays
a rich admixture of goblet cells11,12 against a background of
columnar cells that resemble gastric foveolar cells, which
contain acid sialomucin and neutral mucin of normal gastric
foveolar cells.17–19 This combination of differentiated line-
ages thus resembles type II intestinal metaplasia in the
gastric mucosa, sometimes called the incomplete type,
which includes types II and III depending on whether the
columnar and goblet cells secrete sialomucins (type II) or
sulfomucins (type III).20,21 Accordingly, mucin core proteins
commonly used to categorize lesions of gastric or intestinal
type are both found in specialized Barrett’s epithelium.
Thus, both MUC2 and MUC3, as normally seen in intestinal
epithelium, and MUC1, MUC5AC, and MUC6, as character-
istic of gastric epithelium,17,22 are found in specialized
Barrett’s epithelium, a pattern also reﬂected in trefoil pep-
tide expression.17,23 Important to this discussion is the
striking regional localization of these mucin core proteins
along the gland axis with MUC5AC/TFF1 and MUC2/TFF3
found in the upper portion of the gland, and MUC6 and TFF2
localized in the mucous cells of the Barrett’s gland base
(Figure 1B). This compartmentalization strongly resembles
the basic architecture of the pyloric gland in the gastric
antrum. Leucine-rich repeat-containing G-protein coupled
receptor 5 (LGR5) is thought to locate intestinal stem cells
in mice and humans24–26 and in situ hybridization shows
LGR5 mRNA expression at the junction of the MUC5ACþ/
TFF1þ cells and the MUC6þ/TFF2þ cells, indicating the site
of the stem cell niche.17 This is also the origin of the bidi-
rectional cell ﬂux seen in these glands and reﬂects their
kinetic organization, with maximum proliferative activity in
the midportion as shown by Ki-67.17,27,28
In addition to this canonical specialized gland phenotype
of Barrett’s esophagus, the microscopic phenotype of Bar-
rett’s esophagus includes a wide variety of cell lineages and
proliferative units (illustrated in Figure 4A). First are the
mucinous glands without parietal cells,29,30 variously called
cardiac epithelium by some31 and non-goblet columnar
epithelium by others32: in these glands, the superﬁcial
glandular epithelium is typically composed of mucinouscolumnar cells without goblet cells. The base is formed of
acini lined by MUC6þ/TFF2þ mucinous cells, much like the
Barrett’s gland base already discussed. Some of these glands
may show early evidence of intestinalization, as demon-
strated by villin and CDX-2 expression (reported in 17% and
43% of cases, respectively), although MUC2 is absent.32
Second, oxyntocardiac glands are found throughout the
Barrett’s segment29 and are formally deﬁned as glands
containing a mixture of mucous cells and parietal cells,30–32
which phenocopy normal pyloric epithelium. This gland
phenotype also displays a basic ground plan of superﬁcial
foveolar glandular epithelium and a mucous base formed of
acini lined by MUC6þ/TFF2þ mucinous cells. Note that,
contrary to common belief, parietal cells are not restricted
to corpus-type mucosa and are abundantly found in normal
pyloric mucosa.33 Mature fundic-type glands can also be
found in Barrett’s mucosa.30 These glands display chief cell
and parietal cell differentiation to varying degrees, remi-
niscent of gastric corpus glands.
Finally, glands showing mature intestinal differentiation
may be seen. This can manifest as the complete type of in-
testinal metaplasia (also designated type I) with enter-
ocytes, Paneth cells, and goblet cells secreting sialomucins
and containing MUC2 intestinal mucin, but without gastric
mucin core proteins, This phenotype may be localized to
areas around the gastroesophageal junction.34 More
commonly, canonical specialized Barrett’s glands, as out-
lined previously, show Paneth cell differentiation—possibly
indicating maturation toward the complete intestinal phe-
notype—while retaining foveolar differentiation and gastric
mucin core expression.Barrett’s Glands in Physical Space
There is good evidence for a spatial distribution of the
various phenotypes within the Barrett’s segment: Paull
et al.30 mapped their distribution and in some patients
showed a zonal distribution with either gastric fundic-type
epithelium with parietal and chief cells or cardia type
epithelium interposed between the specialized Barrett’s
glands and the lower esophagus. Such zonation has been
44 McDonald et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 1conﬁrmed31,32,34,35: although the specialized metaplasia in
the more distal segments is always mixed with oxy-
ntocardiac and cardiac glands, specialized metaplasia isusually present as a contiguous zone abutting the squamo-
columnar junction.36,37 Indeed, there is a gradient of goblet
cell density such that there are signiﬁcantly fewer goblet
January 2015 Barrett’s Gland in Phenotype Space 45cells in the distal Barrett’s segment,31 correlated with the
more acidic esophageal luminal pH gradient closer to the
lower esophageal sphincter.38
Others have found the different phenotypes randomly
distributed throughout Barrett’s mucosa,39 but cardiac
mucosa is present throughout the segment, with oxy-
ntocardiac mucosa more frequently found distally,31 which
was conﬁrmed by Going et al.,29 who also found higher
frequencies of cardiac and oxyntocardiac mucosa in the
distal Barrett’s segment, with different mucosal phenotypes
present as a mosaic that varied in proportion with anatomic
site. The evidence strongly suggests that a spatial gradient
of phenotypes exists, with specialized (goblet-containing)
Barrett’s glands concentrated in the proximal segment.The Barrett’s Gland in Time
An important question is whether individual glands lin-
ing Barrett’s esophagus evolve with time; or, once formed,
whether they are phenotypically stable. There are perhaps
two lines of thought that allow us to answer these questions.
First, studies performed after operations such as esoph-
agectomy with gastric pull-up have found that about 50% of
such patients develop columnar epithelium in areas origi-
nally (that is, after surgery) covered with squamous mu-
cosa; persuasively, the length of columnar mucosa increases
with the period of observation.40–47 Importantly, the
phenotype of the columnar epithelium is initially the cardiac
type—mucinous glands lacking parietal cells—which shares
the immunophenotype of cardiac mucosa found in control
patients who had not been subjected to the procedure:
progression to intestinal metaplasia then occurs.43 BMP4
activation, early expression of CDX2, and later expression of
CDX1 and MUC2 are seen progressively.48 Although in
esophagectomy patients cardiac mucosa develops rapidly
(within 1 to 2 years), intestinalization of this columnar
epithelium only occurs after a further 3 to 5 years.43–46,49
However, in other studies, while sucrase-isomaltase
expression appeared within 2 years, specialized intestinal
metaplasia took 10 years to appear.49 Second, analysis of
non-goblet cell Barrett’s mucosa shows evidence of intes-
tinalization: up to 40% of cases show CDX2 and 17% villin
expression,32,50,51 with a similar proportion showing
sucrase-isomaltase and dipeptidyl peptidase IV expres-
sion.52 Moreover, non-goblet cell mucosa is commoner in
younger patients.53Figure 2. (See previous page). The Barrett’s gland as a unit o
Barrett’s phenotype over time in the context of recurrent erosive
of a Barrett’s segment when selection is important: during the es
state, and, where it does occur, during the development of dys
traits may be under selection. (A) At baseline, the endosco
gastroesophageal junction. (B) After chronic gastroduodenal
damaged and eventually ulcerates. (C) A breach in the epithelia
stimulated by inﬂammation. In the acute, proliferative stage of w
secretory and proliferative traits favoring (mucosal) repair. (D) R
lining within the tubular esophagus. As can be seen in other reg
deposition of a complete mucosal unit, including a newly deriv
remodeling stage, this simple glandular phenotype may evolveThus, intestinalization appears to progress with time. It
is natural to ask from where the antecedent columnar-lined
mucosa without goblet cells derives. Much current thought
regards the esophageal stratiﬁed squamous epithelium as
the precursor,54 but a detailed examination of the Barrett’s
lesion itself provides little or no evidence for this view,
suggesting that gastric glands themselves are the origin of
the columnar-lined mucosa without goblet cells.17 Even in
the normal stomach gastric glands with a low number of
parietal and peptic cells are seen near the gastroesophageal
junction. If, as has been repeatedly claimed, this cardiac
mucosa (which is, in effect, columnar epithelium without
goblet cells31,36,37) is itself metaplastic, then it is conceptu-
ally simpler that expansion of Barrett’s follows microerosive
trauma and begins with microscopic foci of cardiac mucosa
at the gastroesophageal junction.55 With recurrent bouts of
reﬂux and ulceration, the cardiac mucosa expands, replacing
the distal esophageal squamous epithelium. This cyclic
expansion model is depicted in Figure 2. This is in effect a
normal wound-healing response, but characterized by sec-
ondary selection for phenotypes best adapted to the local
microenvironment. Migration of the squamocolumnar
junction proximally occurs because esophageal submucosal
glands are seen beneath the cardiac mucosa.31 Patients with
microscopic specialized metaplasia at the cardia have been
seen to progress to macroscopically evident Barrett’s
esophagus.54,55
The evidence thus strongly suggests that Barrett’s glands
show an evolutionary sequence: from columnar-lined mu-
cosa without goblet cells, through glands showing intestinal
gene expression, to specialized metaplastic glands.54,56
(Figure 2, and Figure 4A and B). Solubility of caustic bile
salts depends on luminal pH and is greatest at intermediate
pH ranges seen most proximally.38 Solubilized duodenal bile
salts are a strong inducer of CDX2 expression.57 Combining
this with the increased density of goblet cells proximally
(see the previous discussion), it is tempting to propose that
goblet cell-containing (specialized) glands move proximally
in both time and space and that Barrett’s glands therefore
form a “marching front” adapted for competition with
squamous cells.
Perhaps the erosive microenvironment proximally
(characterized by intermediate pH values, but high solubil-
ity of caustic bile salts) selects for the specialized pheno-
type, while the non-goblet cell glands compete well with
specialized glands distally, where the pH is more acidic, butf selection. This diagram shows the evolution of the glandular
esophagitis. There are various time points within the evolution
tablishment of the segment, during its progression to a stable
plasia and carcinoma. At each of these time points, different
pic squamocolumnar junction coincides with the anatomic
reﬂux, the squamous lining of the esophagus is repeatedly
l lining is followed by a stereotypical wound-healing response
ound healing, competition may be dominated by selection for
epetitive injury leads to cephalad expansion of the glandular
ions of the intestinal tract, remodeling is accompanied by the
ed muscularis mucosae. (E) After the initial proliferative and
to a complex, specialized glandular phenotype.
Figure 3. Clonal expansion of glandular units in the gastrointestinal tract. Glandular units in the gastrointestinal tract
expand as clonal patches through a ﬁssion process. Crypts in the normal colon ﬁssion on average about every 30 years, forming
a small clonal patch.65 Fission is initiated from the stem cell zone at the crypt base (in magenta), after which the crypt unzips
toward the luminal surface (top panel). Glands in the stomach ﬁssion by forming a bud from the stem cell zone at the level of the
neck (in magenta) through localized cell division. The new gland grows down toward the level of the muscularis mucosae
(middle panel). We propose that Barrett’s glands form clonal patches in a similar manner by forming a glandular bud at the level
of the stem cell zone (again in magenta), which is located just above the MUC6/TFF2þ Barrett’s gland base. This bud extends
and unzips toward the luminal surface (bottom panel). Constituent cell types of each glandular unit are indicated per panel.
46 McDonald et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 1bile salts are insoluble.38 Or are specialized glands clonally
puriﬁed and on a trajectory to dominance over time? What
little evidence we have favors the latter hypothesis.
Some evidence for a proximally migrating, marching front
of columnar epithelium replacing eroded squamous epithe-
lium can be gleaned from a recent report by the McKeon
group.58 The investigators used p63null mice to demonstrate
a proximal shift of the squamocolumnar junction. Their dataelegantly demonstrate that stomach-derived columnar
epithelium can expand and cover a denuded esophagus.
However, the differences (anatomically, temporally, and
mechanistically) between this transgenic model and the
development of Barrett’s esophagus in patients are vast, and
future studies will need to address whether the phenotype in
these p63null mice can model the multitude of histologic
forms that deﬁne Barrett’s metaplasia.
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Evolution—Neutral Drift in Metaplasia
We have seen that Barrett’s specialized glands contain
multiple differentiated cell lineages, thus fulﬁlling the
requirement for a true metaplasia, the transformation of one
tissue type into another.59 This involves change in the po-
tential of stem cells, which undergo transcriptional modiﬁ-
cation to deliver a whole series of lineages to give the
several gland phenotypes we observe. If indeed this were a
stem cell change, we would predict that such glands would
be clonal populations. Direct visualization of clonal muta-
tions in the mitochondrial DNA-encoded gene cytochrome c
oxidase (CCO) shows that specialized Barrett’s glands are
clonal60; similarly, the metaplastic crypts of gastric intesti-
nal metaplasia are also clonal.61 What has happened here is
that Barrett’s glands have undergone the process of mono-
clonal conversion, or replacement with a new clone, which
incidentally carries a CCO-mutation so that all contained
lineages also carry this clonal mark. Such CCO mutations are
thought not to confer a ﬁtness advantage,62 so this can be
interpreted in terms of a CCO-mutant stem cell drifting to
ﬁxation within the stem cell niche.
Can such drift be the cause of the conversion of columnar-
lined mucosa to specialized Barrett’s metaplasia? The
evidence indicates that specialized Barrett’s glands were
originally a pyloric-type gastric gland with TFF1þ/MUC5ACþ
and TFF2þ/MUC6þ lineages. A stem cell expressing CDX2
will derive progeny initially expressing intestinal genes such
as villin and sucrase-isomaltase, and a balanced homeostasis
within the gland is achieved via competition between sym-
metrically dividing stem cell cells. Thus, drift governs stem
cell dynamics,63,64 a conclusion now substantiated for human
epithelial stem cells.65 Stochastically, a CDX2þ stem cell may
survive in the niche, and again may undergo niche succession.
Cells that are positive for MUC2 and for TFF3 are not seen in
non-goblet columnar glands; however, once a stem cell under
the transcriptional control of CDX2 or CDX1 switches on
MUC2/TFF3 expression, then by the same process of neutral
competition these cells may survive and come to populate the
niche, leading to the familiar specialized metaplastic gland.
The progressive intestinalization seen in gastric glands with
time suggests that such drift may be biased66 toward niche
succession—that the metaplastic stem cells have a ﬁtness
advantage. Moreover, once phenotypic drift has led to niche
succession and clonal conversion to a totally metaplastic
gland, the process is likely irreversible,59 possibly associated
with the expression of the homeobox gene CDX2 which acti-
vates intestinal differentiation67 in the stomach by Heli-
cobacter pylori infection and in Barrett’s glands by bile/acid
reﬂux.57
It is clear that while distinctively gastric (chief cell) and
intestinal (Paneth cell) lineages are seen in Barrett’s glan-
dular phenotypes, cells simultaneously expressing gastric
and intestinal lineage markers are also present,17 possibly
explained as the progeny of stem cells where CDX2 is
partially activated, allowing mixed gastric and intestinal
gene expression programs in the same cell (Figure 4B). We
can thus propose that the evolutionary sequence leading tospecialized metaplastic glands is non-goblet cell columnar
gland to specialized metaplastic gland.32,49,52,53 This switch
may be associated by pSMAD/CDX2 interaction.56 Moreover,
as we have seen previously, the distribution of gland phe-
notypes from Z-line to cardia in the squamo-oxyntic gap37
complies with this proposal. In this respect, we would
argue that most of the evidence for a direct squamous
epithelial origin of non-goblet cell columnar epithelium is
derived from often ﬂawed experimental models68 and not
from the study of the lesion itself.55
The Life History of Barrett’s Glands
It is possible that columnar metaplasia develops gradually
to involve more of the esophagus36,55,69 or rapidly develops
to its full extent with little subsequent change.70 Certainly the
mean length of columnar epithelium does not increase during
prolonged follow-up observation for as long as 7.3 years.70 At
diagnosis, columnar metaplasia appears to be a stable state
with little evidence of natural progression or regression.
However, it is known that structures such as human small
intestinal and colonic crypts have a life history: in neonatal
life, the early crypts increase their number by the process of
crypt ﬁssion—a crypt divides to make two daughters.71 But
this process continues throughout life—new crypts are
continually generated, albeit at a slow rate. The crypt cycle in
normal adults (the time between two ﬁssion events in a given
crypt) has been variously estimated as 17 to 26 years,72
although it may be as long as 36 years.65 The question is,
do Barrett’s glands have a similar life history? Are they born
by a ﬁssion event from a parent? How long do they live, and
are they lost from the population? These questions are rarely
if ever asked, possibly because we do not know the answers!
But what is clear is that gastric glands, which bear a
considerable relationship at least to specialized metaplastic
glands,17 do have such a life history.
We know little or nothing about the mode of replication
of gastric glands, only that it does occur. For example, we
reported a patch of entirely CCO-mutated gastric glands (or
gastric units) where direct sequencing showed all glands to
contained a clonal mutation (G/A transition at position
2593 in the 16S rRNA [MTRNR2] gene) showing that a
single, wholly mutated gastric gland has expanded by mul-
tiple ﬁssion events to form this clonal patch.73 How does
this expansion take place? This has only really been studied
in the gastric corpus of the hamster in a series of elegant
articles by Hattori.74 The process begins with a doubling of
the number of cells around the circumference of the neck
region of the gland, and some of the proliferating cells
appear to become attached to the opposite side of the lumen
such that the tubule is asymmetrically divided into two. The
smaller tubule then grows to form a new foveolus at the
surface, followed by the formation of a bud at the level of
the neck, by localized cell division, and by the new gland
growing down toward the level of the muscularis mucosae,
by which time the new tubule is completely separated by
stromal ingrowth. Although the location of stem cells in the
human corpus gastric gland is not known, current thought
favors the isthmus/neck region.75 As stated, ﬁssion events
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begins with a budding event in the base of the colonic crypt
where similarly the crypt stem cells reside.76,77 In the
specialized metaplastic glands in Barrett’s esophagus, the
LGR5 stem cell zone is found at the junction of the basal
MUC6þ/TFF2þ cells and the more superﬁcial MUC5ACþ/
TFF1þ and MUC2þ/TFF3þ cells.17 In analogy with the
situation in the gastric corpus and colonic crypt where gland
ﬁssion is initiated from the stem cell zone (at the neck zone
and the base of the crypt, respectively), we might speculate
that Barrett’s glands clonally expand by ﬁssion initiated
from the isthmus region (Figure 3).
But what evidence is there that, in Barrett’s segments,
ﬁssion events occur? Until recently, it was thought that mu-
tations spread through Barrett’s segments in a series of
multiple selective sweeps by new, selectively advantageous
genotypes that swept to ﬁxation in the whole segment,3 so it
was natural to propose that gland ﬁssion was the mecha-
nism.78 In fact, one recent study found only one such case of a
clone that grew to stably dominate the Barrett’s segment.79
However, early mutations at fragile genomic sites and in
genes such as p16 are found throughout the Barrett’s
segment,79,80 and thus, possibly during the establishment of
the segment, gland ﬁssion is important in the spread of such
mutations. However, it is clear that smaller clonal expansions
occur in Barrett’s mucosa,2,80 and thus, as has recently been
shown to be the case in the colon, gland ﬁssion is the
mechanism driving the expansion of clones.
A ﬁnal question must be, is the Barrett’s segment clonal?
This question takes us right back to the beginning of the
evolution of the Barrett’s segment: depending on our view ofFigure 4. (See previous page). The Barrett’s gland in phenoty
phenotypes found in Barrett’s esophagus. The top row shows H
the second row shows an illustration of these glandular phenot
mucosal esophageal glands, double muscularis mucosae) was
show labels denoting the differentiated lineage that (often in co
immunohistochemical markers for these various differentiated
glands are numbered in order of appearance in the main text. (i)
detail in Figure 1. (ii) The non-goblet columnar gland, or cardiac g
of mature Barrett’s glands, save for the absence of MUC2þ go
because they lack CDX2 expression (see Figure 2B). (iii) The ox
yellow) and is functionally equivalent to the pyloric gland. (iv) The
and is functionally equivalent to the glandular phenotype of the
differentiation. Barrett’s glands may show Paneth cell (orange)
indicating further intestinal maturation. (B) Frozen Barrett’s ma
strate) and CDX2 (nuclear labeling, brown substrate). Shown ar
cell differentiation and CDX2 expression that are both absent in
Foveolar differentiation and MUC5AC expression are found in
with CDX2 expression. (C) Barrett’s glands evolve genotypically
pressures of gastroduodenal reﬂux, chronic and acute inﬂamm
Schematic view of the Pareto front in performance space. Ph
separate tasks. The phenotypes that are on the Pareto front (in
front therefore represents the set of best compromises. The ph
observed, because they are dominated by the phenotype(s) on th
be viewed as an integrated biologic system where the phenoty
space. Traits are shown along the axes, which deﬁne an abstract
show traits, not task performance. An optimal phenotype with
studying Barrett’s esophagus from an evolutionary perspective,
between metaplastic phenotypes.the derivation of Barrett’s mucosa, does it arise from a single
(clonal) gland in the cardia, a single squamous epithelial stem
cell, or even a single esophageal gland? This is an intriguing
concept for which there is little evidence either way. Many
Barrett’s segments show early sometimes clonal genetic
events,79 which have been interpreted as indications of
damage rather than a clonal origin. If the segment is clonal, it
implies that a gland with some ancestral phenotype (near-
gastric in phenotype?) clonally expanded and ﬁlled the
segment, then the conversion to other gland types occurred.
These conversions either occurred multiple times, so that the
metaplastic glands represent multiple distinct clones, or once,
and the glands represent a clonal sweep. We propose that
phylogenetic analysis coupled with phenotyping would be
the way to approach this question and, of course, that evo-
lution between phenotypes would be revealed by this
approach, regardless of the underlying clonality of the Bar-
rett’s segment. Although it would be fascinating, an experi-
mental approach may not be feasible at this time.
We have discussed the scope of Barrett’s glandular
phenotypes and made the point that they have a distribution
in space and time. These metaplastic glands also clonally
expand. If, as we propose, the cause of these phenomena is
clonal expansion by ﬁssion (Figure 3), then it follows that
the unit of selection is the gland itself.
The Barrett’s Gland as a Unit of
Selection
There are various time points within the evolution of a
Barrett’s segment when selection is important: during thepe space. (A) Morphologic deﬁnition of the spectrum of gland
&E photomicrographs of the various gland phenotypes, and
ypes (see the article for details). Esophageal derivation (sub-
veriﬁed for all examples shown here. The histology panels
mbination) deﬁnes the speciﬁc metaplasia. (Further details on
lineages along with references are provided in Table 1.) The
The canonical goblet-containing Barrett gland is discussed in
land, closely parallels the makeup and functional organization
blet cells. Foveolar cells are shown in this case in light blue
yntocardiac gland demonstrates parietal cell differentiation (in
fundic-type gland shows chief cell differentiation (light green)
gastric corpus. (v) Barrett’s glands showing mature intestinal
and enterocyte differentiation (not shown), the latter possibly
terial costained for Muc5AC (cytoplasmic labeling, blue sub-
e two neighboring glandular units; the left shows clear goblet
the right gland (type ii and type i in Figure 2A, respectively).
both glands, showing that foveolar maturation is compatible
and phenotypically under the continuous Malthusian selection
ation, clonal competition, and ﬁnally treatment effects. (D)
enotypes can be plotted according to performance on two
red) manage to optimize trade-offs between these tasks. The
enotypes that are behind the front are feasible (white) but not
e Pareto front.13 (E) The glandular phenotypes in Barrett’s can
pe is deﬁned according to a vector of traits within phenotype
three-dimensional space. Note that, in contrast to D, the axes
maximum ﬁtness will occupy a point in phenotype space. By
we may understand the adaptive forces governing transitions
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stable state, and, where it does occur, during the develop-
ment of dysplasia and carcinoma. The available evidence
strongly suggests that the phenotype that is initially selected
after erosion is the non-goblet cell columnar gland, which
initially forms the cardiac-type mucosa (Figure 4A).36,49,53
This is followed by the development of intestinaliza-
tion32,52 and the selection of specialized metaplastic glands
containing goblet cells. The foveolar cells in these glands
coexpress gastric mucin core proteins (MUC5AC) and in-
testinal marker genes (CDX2), still pointing to this transition
(Figure 4B). Importantly, at every point during this
sequence the unit of selection is the gland itself, which
adapts to a range of locally prevailing selection pressures
(Figure 4C). This selection takes place in time and space,
taking several years to complete; although all phenotypes
are generally seen at all levels in the segment, specialized
metaplastic glands are concentrated in the proximal part of
the segment.29 Finally, mutations occur within Barrett’s
glands, leading to the selection of the dysplastic phenotype,
which if low-grade may remain stable for many years.13,81
Even high-grade dysplasia can remain histologically stable
for up to 20 months,82 although recent studies have shown
that sudden, punctuated evolutionary events lead rapid
progression to cancer within a period as short as 4 years,2
implying that very strong selection can occur for an
optimal phenotype. However, the adaptations that this
strongly selected phenotype has developed are
unclear—perhaps they are just fast replicators? Further
research into the functional properties of the dysplastic
gland phenotype may clarify this issue.
We might therefore ask, why is such a broad array of
metaplastic gland phenotypes observed in Barrett’s esoph-
agus to begin with? What explains its protean manifesta-
tion? The concept of selection among different gland
phenotypes is easiest to understand within the context of
malignant progression, where clonal mutations within
growth-promoting genes would be expected to increase the
ﬁtness of mutant glands. These dysplastic glands have
migrated up a ﬁtness landscape to reach an area of higher
ﬁtness. This ﬁtness landscape is much more difﬁcult to
conceptualize for metaplastic Barrett’s esophagus glands. In
the ﬁrst place, although we know their distribution in gen-
eral terms, we have no hard data on the scale of such var-
iations in phenotype in the stable Barrett’s segment. For
example, we are not informed whether metaplastic patches
vary in size along the Barrett’s segment. Nonetheless, gland-
to-gland changes in metaplastic phenotype can be seen in
Barrett’s esophagus (Figure 4B). On an H&E level, the clonal
transition from a non-goblet columnar phenotype to a
specialized Barrett’s gland phenotype (compare phenotypes
ii and i in Figure 4A, respectively) is limited to the acqui-
sition of a few goblet cells. As a result, clonal transitions
between neighboring glands do not stand out as clearly as,
for example, intestinal metaplasia in chronically inﬂamed
corpus mucosa or pseudopyloric glands in Crohn’s ileitis.
Nonetheless, a topographic gland-by-gland comparison of
the heterogeneity of metaplastic phenotypes along the
Barrett’s segment (within and between patients) couldreinforce the concept that Barrett’s esophagus is best
viewed as a patchwork of related, but phenotypically
distinct, clonal units.
Following the above hypothesis that the early Barrett’s
segment is occupied by non-goblet cell Barrett’s, we might
propose that there is strong selection in the toxic gastrodu-
odenal reﬂux environment of Barrett’s esophagus initially for
this phenotype.1 After some time, possibly years, the
specialized metaplastic glands appear; however, these do not
replace the non-goblet cell columnar glands, which remain as
ancestral clones at all levels in the segment while the
specialized glands set up their gradient within the segment.
Because the specialized metaplastic glands rarely if ever
monopolize the segment, selection for them over the non-
goblet cell Barrett’s glands is relatively weak. Clearly, we
lack an exact quantitative formulation of the rate of clonal
expansion of metaplastic clones in the esophagus. Future
studies should address this gap in our understanding. Only
through detailed integration of genotype and phenotype can
we resolve this matter and compare the rate of clonal
expansion of the various metaplastic phenotypes (Figure 4C).
It remains uncertain whether the traits under selection
in the different gland types are the ability to survive acid/
peptic digestion or to reproduce by ﬁssion. Certainly Bar-
rett’s mucosa actively secretes anions and HCO3
, which
buffers acid,83 elaborates a thick mucus coat which protects
against bile and acid,84 and expresses a series of claudins
that resists acid permeation.85 Additionally, genes that
control mucosal repair are up-regulated in Barrett’s
mucosa.14–16 Indeed, there may be multiple other properties
of Barrett’s glands that we have failed to identify but
nevertheless all contribute to ﬁtness. Fitness can thus be
viewed as an aggregate parameter that relates to the all-
around performance of a speciﬁc gland (or gland pheno-
type) relative to the other glands in the segment. Naturally,
the best phenotype for one function is usually not the best
for others—a so-called trade-off,86,87 as seen in nature with
fertility versus offspring survival, or performance measures
such as speed versus endurance, or growth versus shell
robustness in snails. Barrett’s esophagus can similarly be
understood as one ecologic system where the observed
phenotype represents an optimal trade-off between per-
formances on various tasks (Figure 4D). An optimal
phenotype with maximum ﬁtness will occupy a point in
phenotype space although here, as in other cases,13 we do
not know the nature of the ﬁtness, and of course Barrett’s
epithelium performs multiple functions, or tasks, that
contribute to its ﬁtness. It thus becomes important to un-
derstand how such trade-offs affect the phenotypes we ﬁnd;
Pareto optimality can be used to understand such trade-offs
that decide the range of phenotypes (Figure 4E).13,86
We need much more detailed quantitative information
about the distribution of gland phenotypes, and particularly
how the distribution of gland phenotypes evolve over time
within a Barrett’s segment, before developing these argu-
ments further. Of note, patients treated with proton pump
inhibitors versus those without perhaps offer a natural
“experimental system” whereby the effects of reﬂux on
gland evolution can be studied in vivo.
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Selection for Dysplasia/Malignancy
There are few more contentious topics: what is the
phenotype of the Barrett’s gland that is selected for pro-
gression to malignancy? Here, thought is sharply divided,
with one school ﬁrmly believing that without intestinal
metaplasia (ie, the presence of goblet cells) there is no
proven risk of neoplastic progression,88 while the other
avers that columnar non-goblet epithelium is fully capable
of progression89,90 and that there are thus multiple path-
ways of carcinogenesis in Barrett’s esophagus.91 If we
accept the former case, we should of course ask why in-
testinal metaplasia progresses and the non-goblet cell
phenotype does not. Goblet cells are usually regarded as
terminally differentiated cells and as such are not strong
candidates for a cell of origin; indeed, it has been suggested
that the induction of goblet cell differentiation in Barrett’s
mucosa might be an effective therapeutic strategy.92 Could it
be that goblet cells are merely a marker for malignant
predisposition?8 Goblet cells are effectively the most
extreme marker of intestinalization, so could it also be that
the more extreme the expression of the intestinal phenotype
the more likely is selection for neoplastic progression,
possibly due to an intrinsically higher mutation rate or
because the intragland clonal dynamics are different, with
fewer stem cells?
Could those cases of non-goblet cell phenotype that
progress be the fraction of the non-goblet cell phenotype
that also shows evidence of intestinal differentiation,9,32
expressing markers such as MUC2, DAS-1, villin, and
CDX2? It is possible, although carcinomas of complete
gastric immunophenotype have been associated with com-
plete gastric (foveolar) dysplasia and the gastric (non-goblet
cell) metaplastic immunophenotype.91 The metaplastic non-
goblet cell phenotype can be associated with chromosomal
instability90 and DNA abnormalities,93 but, then again,
possibly not with the same high frequency as metaplasia
with goblet cells.6 Naturally, this discussion is predicated on
the goblet cell lineage being terminally differentiated: there
is evidence that goblet cell populations in gastric intestinal
metaplasia can retain proliferative capacity,94 in which case
this assumption may need revisiting.
However, from the evolutionary standpoint, specialized
epithelium has on average gone through at least one addi-
tional bottleneck event compared to nonspecialized
epithelium. Because the number of bottleneck events may
relate to cancer risk, and every clonal patch of specialized
epithelium represents one separate ecologic bottleneck
event, this may explain the relatively increased risk of
cancer in stretches of goblet-containing specialized epithe-
lium. Thus, while nonspecialized epithelium is not risk free,
if indeed the gland is the unit of selection and there is
directional evolution, then specialized epithelium may be
placed one bottleneck farther down the road to progression.
Perhaps a reasonable standpoint would be that any Barrett’s
metaplasia can be selected for malignant progression but
that the selection is biased toward the intestinal phenotype.
Again, quantitative information on the life histories ofglandular phenotypes would be a ﬁrst step toward resolving
this issue.
The Barrett’s Gland in Regression
The fact that Barrett’s mucosa in regression after acid-
inhibition or radiofrequency ablation apparently reverts
directly to a stratiﬁed squamous phenotype without any
intermediary has elicited little comment. However, it is
clearly not the Barrett’s mucosa itself that differentiates
back to squamous epithelium,95 but rather the squamous
epithelium emanates from an alternative clone source from
within esophageal gland ducts.96 The evolutionary me-
chanics surrounding this change are obscure—why the
squamous progeny of stem cells located in gland ducts
should have a ﬁtness advantage over cardiac or Barrett’s
mucosa is as yet unknown. One recent study in fact indicates
that after complete endoluminal eradication of Barrett’s
mucosa and a documented return to squamous epithelium,
nearly half of all patients show a return of Barrett’s mucosa,
in some cases with high-grade lesions.97 Clearly this is an
area for future research, in particular in relation to the
initiation and progression of Barrett’s in a high-risk cohort.
Conclusions
Increasingly, we look at genomics for the answers we
need concerning the evolution of Barrett’s esophagus, often
to the total exclusion of phenotype considerations.2 How-
ever, it is clear from this discussion that such an approach is
likely to be ultimately incomplete, and that only by the
integration of Barrett’s glands in genotype and phenotype
space can we expect to answer the many unanswered
questions that surround this enigmatic lesion.
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